{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:45Z","timestamp":1791550365091,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40119-025-00397-6","type":"journal-article","created":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T20:06:06Z","timestamp":1740341166000},"page":"101-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiovascular Outcomes of Early LDL-C Goal Achievement in Patients with Very-High-Risk ASCVD"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-948X","authenticated-orcid":false,"given":"Ah-Ram","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1366-8275","authenticated-orcid":false,"given":"Ji Ye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-5321","authenticated-orcid":false,"given":"Minkyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-5673","authenticated-orcid":false,"given":"Hojoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-6310","authenticated-orcid":false,"given":"Yeon-Hee","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-6390","authenticated-orcid":false,"given":"Imjin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-2112","authenticated-orcid":false,"given":"Hee Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-0891","authenticated-orcid":false,"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-8632","authenticated-orcid":false,"given":"Osung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-5149","authenticated-orcid":false,"given":"Tae Joon","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun U.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3610-486X","authenticated-orcid":false,"given":"Young-Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"issue":"1","key":"397_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacasi.2021.04.007","volume":"1","author":"D Zhao","year":"2021","unstructured":"Zhao D. Epidemiological features of cardiovascular disease in Asia. J Am College Cardiol Asia. 2021;1(1):1\u201313. https:\/\/doi.org\/10.1016\/j.jacasi.2021.04.007.","journal-title":"J Am College Cardiol Asia"},{"issue":"1","key":"397_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"1","key":"397_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1186\/s12889-019-7439-0","volume":"19","author":"H Kim","year":"2019","unstructured":"Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Y, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. https:\/\/doi.org\/10.1186\/s12889-019-7439-0.","journal-title":"BMC Public Health"},{"issue":"24","key":"397_CR4","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/circulationaha.116.024604","volume":"134","author":"KK Ray","year":"2016","unstructured":"Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation. 2016;134(24):1931\u201343. https:\/\/doi.org\/10.1161\/circulationaha.116.024604. (Epub 20161024).","journal-title":"Circulation"},{"issue":"e25","key":"397_CR5","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.15420\/japsc.2022.26","volume":"2","author":"F He","year":"2023","unstructured":"He F, Page JH, Tandi J, Ghosh A, Liman C, Sarkar J, et al. Major adverse cardiovascular event risk prediction in Asian patients after myocardial infarction: a novel, dynamic, machine-learning approach. J Asian Pacific Soc Cardiol. 2023;2(e25):2023. https:\/\/doi.org\/10.15420\/japsc.2022.26.","journal-title":"J Asian Pacific Soc Cardiol"},{"issue":"6","key":"397_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.18553\/jmcp.2015.21.6.443","volume":"21","author":"JS Korsnes","year":"2015","unstructured":"Korsnes JS, Davis KL, Ariely R, Bell CF, Mitra D. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Spec Pharm. 2015;21(6):443\u201350. https:\/\/doi.org\/10.18553\/jmcp.2015.21.6.443.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"397_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12872-023-03518-y","volume":"23","author":"K Steen Carlsson","year":"2023","unstructured":"Steen Carlsson K, Nilsson K, Wolden ML, Faurby M. Economic burden of atherosclerotic cardiovascular disease: a matched case-control study in more than 450,000 Swedish individuals. BMC Cardiovasc Disord. 2023;23(1):483. https:\/\/doi.org\/10.1186\/s12872-023-03518-y. (Epub 20230929).","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"397_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C Reduction Post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in Collaboration With the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939\u201349. https:\/\/doi.org\/10.1093\/ehjacc\/zuac123.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"5","key":"397_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.amjcard.2005.04.029","volume":"96","author":"GC Fonarow","year":"2005","unstructured":"Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96(5):611\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2005.04.029.","journal-title":"Am J Cardiol"},{"issue":"24","key":"397_CR10","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"397_CR11","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"397_CR12","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for early reduction of LDL\u00a0cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am College Cardiol. 2019;74(20):2452\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.010. (Epub 20190831).","journal-title":"J Am College Cardiol"},{"issue":"5","key":"397_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/clc.23600","volume":"44","author":"NR Desai","year":"2021","unstructured":"Desai NR, Wade RL, Xiang P, Pinto L, Nunna S, Wang X, et al. Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab. Clin Cardiol. 2021;44(5):715\u201322. https:\/\/doi.org\/10.1002\/clc.23600. (Epub 20210324).","journal-title":"Clin Cardiol"},{"issue":"3","key":"397_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","volume":"42","author":"J Schubert","year":"2021","unstructured":"Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42(3):243\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1011.","journal-title":"Eur Heart J"},{"issue":"1","key":"397_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1253\/circj.CJ-14-0877","volume":"79","author":"A Izawa","year":"2015","unstructured":"Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, et al. Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction \u2013 ALPS-AMI study. Circ J. 2015;79(1):161\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-14-0877. (Epub 20141112).","journal-title":"Circ J"},{"issue":"Suppl 18","key":"397_CR16","doi-asserted-by":"publisher","first-page":"S2149","DOI":"10.21037\/jtd.2018.06.46","volume":"10","author":"C Kim","year":"2018","unstructured":"Kim C, Choi D. Timing of high intensity statin for acute coronary syndrome: How earlier initiation makes better? J Thorac Dis. 2018;10(Suppl 18):S2149\u201352. https:\/\/doi.org\/10.21037\/jtd.2018.06.46.","journal-title":"J Thorac Dis"},{"issue":"1","key":"397_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10557-021-07255-2","volume":"37","author":"O Kwon","year":"2023","unstructured":"Kwon O, Na W, Hur J, Kim JH, Jun TJ, Kang HJ, et al. Cardiovascular event rates in statin-treated Korean patients with cardiovascular disease: estimates from a real-world population using electronic medical record data. Cardiovasc Drugs Ther. 2023;37(1):129\u201340. https:\/\/doi.org\/10.1007\/s10557-021-07255-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"397_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4258\/hir.2013.19.2.102","volume":"19","author":"S-Y Shin","year":"2013","unstructured":"Shin S-Y, Lyu Y, Shin Y, Choi HJ, Park J, Kim W-S, et al. Lessons learned from development of de-identification system for biomedical research in a Korean Tertiary Hospital. Healthcare Inform Res. 2013;19(2):102\u20139. https:\/\/doi.org\/10.4258\/hir.2013.19.2.102.","journal-title":"Healthcare Inform Res"},{"key":"397_CR19","doi-asserted-by":"publisher","unstructured":"2015 Korean Guidelines for the Management of Dyslipidemia: executive summary (English Translation). Korean Circulation Journal. 2016;46(3):275\u2013306. https:\/\/doi.org\/10.4070\/kcj.2016.46.3.275 (Epub 20160527).","DOI":"10.4070\/kcj.2016.46.3.275"},{"issue":"34","key":"397_CR20","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"6","key":"397_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127835","volume":"10","author":"T Miura","year":"2015","unstructured":"Miura T, Izawa A, Motoki H, Miyashita Y, Kashima Y, Ebisawa S, et al. Clinical impact of rapid reduction of low-density lipoprotein cholesterol level on long-term outcome of acute myocardial infarction in the statin era: subanalysis of the ALPS-AMI study. PLoS ONE. 2015;10(6): e0127835. https:\/\/doi.org\/10.1371\/journal.pone.0127835. (Epub 20150617).","journal-title":"PLoS ONE"},{"issue":"15","key":"397_CR22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med. 2004;350(15):1495\u2013504. https:\/\/doi.org\/10.1056\/NEJMoa040583. (Epub 20040308).","journal-title":"New Engl J Med."},{"issue":"32","key":"397_CR23","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"21","key":"397_CR24","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"issue":"11","key":"397_CR25","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2020","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020;28(11):1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"397_CR26","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.atherosclerosissup.2021.01.009","volume":"42","author":"U Landmesser","year":"2020","unstructured":"Landmesser U, Pirillo A, Farnier M, Jukema JW, Laufs U, Mach F, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS patient pathway project. Atheroscler Suppl. 2020;42:e49\u201358. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2021.01.009.","journal-title":"Atheroscler Suppl"},{"issue":"9","key":"397_CR27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. J Am College Cardiol. 2021;6(9):1060\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"J Am College Cardiol"},{"key":"397_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","volume":"246","author":"\u017d Reiner","year":"2016","unstructured":"Reiner \u017d, De Backer G, Fras Z, Kotseva K, Tokg\u00f6zoglu L, Wood D, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243\u201350. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.018.","journal-title":"Atherosclerosis"},{"issue":"1","key":"397_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/clc.23935","volume":"46","author":"NR Desai","year":"2023","unstructured":"Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13\u201321.","journal-title":"Clin Cardiol"},{"issue":"15","key":"397_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/circulationaha.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/circulationaha.122.061620. (Epub 2022\/08\/30).","journal-title":"Circulation"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00397-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00397-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:59:34Z","timestamp":1741625974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00397-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00397-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hojoon Lee and Yeon-Hee Baek are employees of Amgen Korea. Ah-Ram Kim, Ji Ye Han, Minkyoung Kim, Imjin Ahn, Hee Jun Kang, Ji Seon Oh, Ju Hyeon Kim, Osung Kwon, Tae Joon Jun, Sun U. Kwon, and Young-Hak Kim have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the institutional review board of Asan Medical Center (Institutional Review Board number: 2021\u20130192), which granted permission to access and analyze the database utilized in this study. This study was conducted in accordance with the Helsinki Declaration. The requirement to obtain informed consent was waived due to the minimal-risk nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}